Essential thrombocythemia (ET) is a rare chronic myeloproliferative disease characterized by the overproduction of platelets. While the etiology of ET is not fully understood, a genetic mutation may be accountable in most cases. With proper treatment, patients with the disease generally have normal life expectancies that are of excellent quality. Depending on the severity of the patient’s diagnosis, different drug classes can be used to target appropriate mechanisms. Anticoagulant therapies, for example, can be used to prevent clotting, while PDE-3 inhibitors such as anagrelide (Takeda’s Agrylin, generics) can be used to reduce the number of platelets.
Markets covered: United States
Key drugs: Anagrelide, aspirin, edoxaban, enoxaparin, hydroxyurea, rivaroxaban, ruxolitinib
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.